
Veeva Systems
VEEV · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $50,7 bn
- Div. yield
- —
- Year to date
- +35,1%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
8 ✓ · 0 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 47,3 | 55,5 | 25,1 |
| Forward P/E | 33,6 | — | 16,2 |
| PEG | 2,1 | — | 2,2 |
| P/S | 13,9 | 13,4 | 2,2 |
| EV/EBITDA | 43,2 | 52,4 | 17,3 |
| P/FCF | 29,3 | — | 19,5 |
| P/B | 6,5 | 7,0 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 35 analysts
- Buy
- 26
- Hold
- 8
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q2 2027 | 2,27 | 2,35 | Up +3,7% |
| Q1 2027 | 2,17 | 2,24 | Up +3,0% |
| Q4 2026 | 1,97 | 2,06 | Up +4,5% |
| Q3 2026 | 1,99 | 2,04 | Up +2,6% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 928 m | 883 m | 836 m | 811 m | 789 m | 759 m | 721 m | 699 m | 676 m | 650 m | 631 m | 617 m |
| EPS | 1,66 | 1,57 | 1,48 | 1,40 | 1,19 | 1,37 | 1,17 | 1,13 | 1,04 | 0,98 | 0,90 | 0,83 |
| Margin | 29,5% | 29,6% | 29,2% | 29,1% | 25,4% | 30,1% | 27,1% | 26,6% | 25,3% | 24,9% | 23,4% | 21,9% |
| FCF | 239 m | 1,13 bn | 107 m | 193 m | 238 m | 877 m | 69,5 m | 164 m | 92,9 m | 764 m | 57,8 m | 82,6 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $16,8 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| faddis jonathan14 Oct 2026 · sale | $211 120 | 708 | $298,19 |
| faddis jonathan14 Oct 2026 · sale | $291 810 | 975 | $299,29 |
| faddis jonathan14 Oct 2026 · sale | $1,05 m | 3 515 | $300,14 |
| rizzo daniel j2 Oct 2026 · sale | $88 662 | 321 | $276,21 |
| rizzo daniel j2 Oct 2026 · sale | $1,25 m | 4 520 | $276,53 |
| schwenger thomas d.14 Sep 2026 · sale | $265 200 | 1 000 | $265,20 |
| hung priscilla9 Sep 2026 · sale | $195 780 | 750 | $261,04 |
| schwenger thomas d.27 Aug 2026 · sale | $2,81 m | 10 000 | $281,33 |
| schwenger thomas d.13 Aug 2026 · sale | $456 620 | 1 819 | $251,03 |
| schwenger thomas d.13 Aug 2026 · sale | $8,31 m | 33 181 | $250,44 |
| schwenger thomas d.13 Aug 2026 · sale | $241 910 | 1 000 | $241,91 |
| schwenger thomas d.16 Jul 2026 · sale | $1,00 m | 5 000 | $200,00 |
| hung priscilla30 Apr 2026 · sale | $116 730 | 750 | $155,64 |
| hung priscilla10 Apr 2026 · sale | $115 125 | 750 | $153,50 |
| schwenger thomas d.5 Mar 2026 · sale | $200 000 | 1 000 | $200,00 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 16 Oct 2013
- Website
- www.veeva.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- 3 Dec 2026, after close
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
HUMHumana | $461,25 | 61★★★★★★★★would watch | 44,0 | +22,0% | 0,8% |
IDXXIdexx Laboratories | $700,65 | 83★★★★★★★★★would consider | 47,2 | +11,9% | 25,4% |
BDXBecton Dickinson | $216,47 | 38★★★★★★★would not consider | 51,8 | −2,6% | 4,5% |
EWEdwards Lifesciences | $107,11 | 56★★★★★★★★would watch | 60,3 | +13,4% | 15,2% |
BSXBoston Scientific | $43,69 | 83★★★★★★★★★would consider | 18,4 | +8,9% | 16,6% |
Ratio — a score by our methodology, not an investment recommendation.




